Nicox
en
fr
Toggle Menu
About Us
Visible Science
Leadership Team
Board of Directors
Partnerships
Portfolio and Disease Areas
Nicox’s innovative portfolio
Disease focus areas
Our portfolio at a glance
Nitric Oxide Donation
Publications
Investors
Stock Information
Financial and Regulatory Information
Shareholder Meetings
Corporate Presentation
Questions & Answers
Corporate Governance
News and Events
Press Releases
Events and Conferences
Videos
Contact Us
Contact Details
Main subsidiaries
Job opportunities
Email alerts
NCX 470, a Nitric Oxide Donating Bimatoprost versus Latanoprost Has Greater Proportion of Subjects Achieving ≥10 mmHg IOP Decrease in Phase 3 Trial
July 3, 2023
← Back to blog page
Cookies
By continuing to use this website, you agree to our
Cookie Policy
.
Accept
